Biolidics Ltd. (SG:8YY)
SGX:8YY
Want to see SG:8YY full AI Analyst Report?
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$88.41M
Enterprise ValueS$90.26M
Total Cash (Recent Filing)S$557.00K
Total Debt (Recent Filing)S$2.41M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueBiolidics sells test kits plus per-test consumables, creating a repeat-purchase revenue stream tied to installed usage. Over 2-6 months this dynamics supports steadier unit economics and revenue visibility as users continue buying consumables after initial instrument adoption.
Revenue Rebound / Commercial TractionA near 200% revenue jump in 2025 signals renewed market demand or improved commercialization. This kind of demand shift can provide the sales base needed to achieve scale, improve gross margins, and validate product-market fit if the company sustains growth beyond the one-year rebound.
Lean Operating FootprintA very small headcount implies low fixed overhead and the ability to extend cash runway while pursuing growth. With a lean team the company can leverage distribution partners and outsourcing to scale revenue without large incremental SG&A, helping margin expansion if sales rise.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business does not yet self-fund its operations. Over the medium term this forces reliance on external financing or equity raises, which can dilute shareholders and limit ability to invest in commercialization or R&D if funding conditions tighten.
Meaningful Leverage And Thin EquityDebt materially exceeds the narrow equity base, and a history of negative equity highlights balance-sheet instability. This constrained capital structure reduces financial flexibility, raises refinancing risk, and can increase cost of capital, especially if operating performance falters.
Ongoing Unprofitability And Volatile MarginsRecurrent net losses and volatile margins show the business has not yet achieved operating leverage or consistent profitability. Even with rising revenue, sustained losses imply structural issues in cost base or pricing that must be addressed for durable free cash flow and long-term viability.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$88.41M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Aug 18, 2026 which is in 110 days.
How were Biolidics Ltd.’s earnings last quarter?
Currently, no data Available
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biolidics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.
Technical Analysis
Cordlife Group
―
ISEC Healthcare Ltd
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Singapore Institute of Advanced Medicine Holdings Ltd.
―